Lead Product(s): VAL301
Therapeutic Area: Obstetrics/Gynecology (Women’s Health)
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 01, 2020
Agreement signed with the company will see VAL301 evaluated for the purpose of contemplating a potential future license for the treatment of endometriosis.